Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Institutional & Insider Ownership
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations for Tarsus Pharmaceuticals and Voyager Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 0 | 1 | 5 | 1 | 3.00 |
| Voyager Therapeutics | 0 | 1 | 6 | 1 | 3.00 |
Earnings and Valuation
This table compares Tarsus Pharmaceuticals and Voyager Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $17.45 million | 80.81 | -$135.89 million | ($4.48) | -8.27 |
| Voyager Therapeutics | $143.77 million | 3.03 | $132.33 million | ($0.05) | -160.20 |
Voyager Therapeutics has higher revenue and earnings than Tarsus Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Tarsus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Profitability
This table compares Tarsus Pharmaceuticals and Voyager Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -180.00% | -63.99% | -47.64% |
| Voyager Therapeutics | 6.28% | 3.31% | 2.33% |
Summary
Voyager Therapeutics beats Tarsus Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
